Mainz Biomed B.V. (MYNZ) Financial Ratios
6 years of historical data (2019–2024) · Healthcare · Medical - Diagnostics & Research
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.11
↓-100% vs avg
5yr avg: 247.25
30Y Low0.7·High0.7
ROE
↑
-465.8%
-11% vs avg
5yr avg: -418.4%
30Y Low-466%·High-259%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MYNZ Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Mainz Biomed B.V. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Market Cap | $677764 | $4M | $754M | $4.0B | $3.0B | — | — |
| Enterprise Value | $-2286525 | $1M | $754M | $4.0B | $3.0B | — | — |
| P/E Ratio → | -0.03 | — | — | — | — | — | — |
| P/S Ratio | 0.76 | 4.68 | 841.61 | 7588.04 | 5190.71 | — | — |
| P/B Ratio | 0.11 | 0.69 | 231.95 | 285.24 | 471.12 | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
MYNZ EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.36 | 842.00 | 7561.78 | 5180.05 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
MYNZ Profitability
Margins and return-on-capital ratios measuring operating efficiency
Mainz Biomed B.V. earns an operating margin of -2091.2%. Operating margins have expanded from -4990.6% to -2091.2% over the past 3 years, signaling improving operational efficiency. A negative ROE of -465.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Gross Margin | 64.3% | 64.3% | 56.9% | 34.4% | 30.8% | 24.9% | -21.8% |
| Operating Margin | -2091.2% | -2091.2% | -2975.5% | -4990.6% | -1684.4% | -155.2% | -327.6% |
| Net Profit Margin | -2421.8% | -2421.8% | -2936.5% | -4992.2% | -2024.8% | -118.9% | -340.1% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| ROE | -465.8% | -465.8% | -303.2% | -258.6% | -645.9% | — | — |
| ROA | -151.2% | -151.2% | -147.5% | -174.7% | -218.2% | -84.5% | -133.7% |
| ROIC | -419.7% | -419.7% | -1056.9% | -10104.6% | -4482.9% | -306.2% | — |
| ROCE | -277.8% | -277.8% | -240.4% | -214.2% | -224.6% | -673.3% | -359.8% |
MYNZ Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $6M exceeds total debt of $3M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.54 | 0.54 | 2.28 | 0.23 | 0.41 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.49 | 0.11 | -0.99 | -0.97 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -17.39 | -17.39 | -32.91 | -91.40 | -28.67 | -2.85 | -4.57 |
Net cash position: cash ($6M) exceeds total debt ($3M)
MYNZ Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.32x means Mainz Biomed B.V. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 4.33x to 1.32x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 1.32 | 1.32 | 0.97 | 4.33 | 7.11 | 0.27 | 0.57 |
| Quick Ratio | 1.26 | 1.26 | 0.91 | 4.29 | 7.11 | 0.27 | 0.57 |
| Cash Ratio | 1.05 | 1.05 | 0.77 | 4.04 | 6.46 | 0.17 | 0.44 |
| Asset Turnover | — | 0.07 | 0.06 | 0.03 | 0.06 | 0.73 | 0.39 |
| Inventory Turnover | 0.86 | 0.86 | 0.63 | 1.98 | — | — | — |
| Days Sales Outstanding | — | 87.27 | 144.50 | 178.50 | 11.23 | 32.72 | 52.92 |
MYNZ Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Mainz Biomed B.V. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $968234 | $16M | $14M | $7M | $6M | $12M |
Peer Comparison
Compare MYNZ with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MYNZYou | $677764 | -0.0 | — | — | 64.3% | -2091.2% | -465.8% | -419.7% | — |
 EXAS | $20B | -95.4 | — | 56.1 | 69.7% | -6.4% | -8.7% | -3.6% | — |
 GKOS | $8B | -40.7 | — | — | 77.5% | -17.1% | -26.4% | -9.2% | — |
 NTRA | $28B | -127.8 | — | 252.3 | 64.8% | -13.4% | -14.3% | -36.1% | — |
 SDGR | $981M | -9.3 | — | 78.8 | 55.7% | -65.2% | -26.3% | -39.4% | — |
 GH | $13B | -28.8 | — | — | 64.5% | -44.4% | — | -34.9% | — |
 ILMN | $22B | 26.0 | 20.0 | 23.1 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 CERS | $523M | -31.8 | — | 61.4 | 53.5% | -17.6% | -25.6% | -19.7% | — |
 TMO | $173B | 26.2 | 18.7 | 27.5 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 DHR | $121B | 34.0 | 17.8 | 23.0 | 60.9% | 20.9% | 7.1% | 5.9% | 2.4 |
 BIO | $7B | 9.1 | 16.5 | 18.3 | 52.0% | 10.5% | 10.8% | 2.6% | 3.2 |
| Healthcare Median | — | 22.2 | 14.4 | 18.6 | 64.0% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
See MYNZ's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MYNZ Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MYNZ vs EXAS
Side-by-side business, growth, and profitability comparison vs Exact Sciences Corporation.
Start ComparisonMYNZ — Frequently Asked Questions
Quick answers to the most common questions about buying MYNZ stock.
What is Mainz Biomed B.V.'s P/E ratio?
Mainz Biomed B.V.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
What is Mainz Biomed B.V.'s ROE?
Mainz Biomed B.V.'s return on equity (ROE) is -465.8%. The historical average is -342.5%.
Is MYNZ stock overvalued?
Based on historical data, Mainz Biomed B.V. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Mainz Biomed B.V.'s profit margins?
Mainz Biomed B.V. has 64.3% gross margin and -2091.2% operating margin.